eligibility_summary
Eligible: adults ≥18, newly diagnosed MZL, measurable disease, ECOG≤2, life ≥12 wks, no prior therapy, adequate marrow/organ, labs w/in 7 d (Hb≥90, ANC≥1.5, PLT≥100, liver/kidney/coag OK), negative pregnancy test/contraception. Exclude: prior PI3K, other active cancer <3 y, CNS disease, active infection, severe/uncontrolled CV, ILD, hepatic (active HBV/HCV or Child-Pugh B/C), or renal failure on dialysis, uncontrolled effusions, FBG>10, proteinuria>1 g/d, immunodeficiency, other serious illness.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06592170 tests linperlisib plus obinutuzumab as first-line therapy for marginal zone lymphoma. Linperlisib is an oral small‑molecule PI3Kδ inhibitor that blocks B‑cell receptor signaling, suppressing the PI3K–AKT–mTOR pathway to inhibit malignant B‑cell proliferation/survival and potentially dampen pro‑tumor immune cells (e.g., Tregs). Obinutuzumab is a glycoengineered type II anti‑CD20 monoclonal antibody that targets CD20+ B cells, inducing direct cell death and enhanced ADCC/ADCP and complement-mediated cytotoxicity. Targeted cells/pathways: CD20+ marginal zone B cells, BCR/PI3Kδ–AKT–mTOR signaling, Fc‑mediated immune effector pathways.